Relmada Therapeutics (RLMD) Non-cash Items (2017 - 2026)
Relmada Therapeutics (RLMD) reported Non-cash Items of $37.9 million for Q1 2026, up 333.51% year-over-year from $8.7 million in Q1 2025, and up 448.42% on a QoQ basis from $6.9 million in Q4 2025.
Relmada Therapeutics (RLMD) has 10 years of Non-cash Items data on file, last reported at $37.9 million in Q1 2026.
- Quarterly Non-cash Items rose 333.51% year-over-year to $37.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $37.9 million (up 333.51% YoY) and the FY2025 annual result came in at $6.9 million, down 27.06% from the prior year.
- Non-cash Items climbed to $37.9 million in Q1 2026 per RLMD's latest filing, from $6.9 million in the prior quarter.
- Across five years, Non-cash Items topped out at $37.9 million in Q1 2026 and bottomed at $352084.0 in Q2 2024.
- The 5-year median for Non-cash Items is $6.9 million (2025), against an average of $8.2 million.
- The widest annual swing landed in 2023, when Non-cash Items jumped 2575.46%; it then slumped 93.72% in 2024.
- Tracing RLMD's Non-cash Items over 5 years: stood at $417998.0 in 2022, then jumped by 2575.46% to $11.2 million in 2023, then fell by 15.23% to $9.5 million in 2024, then decreased by 27.06% to $6.9 million in 2025, then jumped by 448.42% to $37.9 million in 2026.
- Per Business Quant, the three latest RLMD Non-cash Items figures stand at $37.9 million (Q1 2026), $6.9 million (Q4 2025), and $8.7 million (Q1 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Relmada Therapeutics | 595.35 Mn | 595.35 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 37.92 Mn |
| Mar 31, 2026 | 37.92 Mn |
| Dec 31, 2025 | 6.92 Mn |
| Dec 31, 2025 | 6.92 Mn |
| Mar 31, 2025 | 8.75 Mn |
| Mar 31, 2025 | 8.75 Mn |
| Dec 31, 2024 | 9.48 Mn |
| Dec 31, 2024 | 9.48 Mn |
| Sep 30, 2024 | 8.89 Mn |
| Sep 30, 2024 | 8.89 Mn |
| Jun 30, 2024 | 352,084.00 |
| Jun 30, 2024 | 352,084.00 |
| Mar 31, 2024 | 7.95 Mn |
| Mar 31, 2024 | 7.95 Mn |
| Dec 31, 2023 | 11.18 Mn |
| Dec 31, 2023 | 11.18 Mn |
| Sep 30, 2023 | 6.56 Mn |
| Sep 30, 2023 | 6.56 Mn |
| Jun 30, 2023 | 5.60 Mn |
| Jun 30, 2023 | 5.60 Mn |
| Mar 31, 2023 | 4.77 Mn |
| Mar 31, 2023 | 4.77 Mn |
| Dec 31, 2022 | 417,998.00 |
| Dec 31, 2022 | 417,998.00 |
| Sep 30, 2022 | 3.71 Mn |
| Sep 30, 2022 | 3.71 Mn |
| Jun 30, 2022 | 7.70 Mn |
| Jun 30, 2022 | 7.70 Mn |
| Mar 31, 2022 | 2.75 Mn |
| Mar 31, 2022 | 2.75 Mn |
| Dec 31, 2021 | 2.14 Mn |
| Dec 31, 2021 | 2.14 Mn |
| Sep 30, 2021 | 2.08 Mn |
| Sep 30, 2021 | 2.08 Mn |
| Jun 30, 2021 | 1.79 Mn |
| Jun 30, 2021 | 1.79 Mn |
| Mar 31, 2021 | 1.41 Mn |
| Mar 31, 2021 | 1.41 Mn |
| Dec 31, 2020 | 1.24 Mn |
| Dec 31, 2020 | 1.24 Mn |
| Sep 30, 2020 | 982,608.00 |
| Sep 30, 2020 | 982,608.00 |
| Jun 30, 2020 | 914,103.00 |
| Jun 30, 2020 | 914,103.00 |
| Mar 31, 2020 | 116,000.00 |
| Mar 31, 2020 | 116,000.00 |
| Sep 30, 2019 | 547,481.00 |
| Sep 30, 2019 | 547,481.00 |
| Jun 30, 2019 | 1.61 Mn |
| Jun 30, 2019 | 1.61 Mn |
| Mar 31, 2019 | 1.28 Mn |
| Mar 31, 2019 | 1.28 Mn |
| Dec 31, 2018 | 949,118.00 |
| Dec 31, 2018 | 949,118.00 |
| Sep 30, 2018 | 788,300.00 |
| Sep 30, 2018 | 788,300.00 |
| Jun 30, 2018 | 81,000.00 |
| Jun 30, 2018 | 81,000.00 |
| Mar 31, 2018 | 81,000.00 |
| Mar 31, 2018 | 81,000.00 |
| Dec 31, 2017 | 414,890.00 |
| Dec 31, 2017 | 414,890.00 |
| Jun 30, 2017 | 6,150.00 |
| Jun 30, 2017 | 6,150.00 |